Effect of 7-valent pneumococcal conjugate vaccine on nasopharyngeal carriage with Haemophilus influenzae and Moraxella catarrhalis in a randomized controlled trial

Abstract Seven-valent CRM197-conjugated pneumococcal conjugate vaccine (PCV7CRM197 ) reduces both vaccine serotype nasopharyngeal colonization and vaccine serotype acute otitis media by 50–60%. However, overall pneumococcal carriage and impact on otitis media are partly offset by concomitant increas...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 29; no. 44; pp. 7595 - 7598
Main Authors van Gils, Elske J.M, Veenhoven, Reinier H, Rodenburg, Gerwin D, Hak, Eelko, Sanders, Elisabeth A.M
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Ltd 13.10.2011
Elsevier
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Seven-valent CRM197-conjugated pneumococcal conjugate vaccine (PCV7CRM197 ) reduces both vaccine serotype nasopharyngeal colonization and vaccine serotype acute otitis media by 50–60%. However, overall pneumococcal carriage and impact on otitis media are partly offset by concomitant increase of nonvaccine serotypes. We investigated in a randomized controlled trial the impact of 2-doses and 2 + 1-doses of PCV7CRM197 on carriage of Streptococcus pneumoniae and of other nasopharyngeal commensals and well-known otitis media pathogens, Haemophilus influenzae and Moraxella catarrhalis, in children. Nasopharyngeal swabs were collected at the age of 6 weeks and at 6, 12, 18 and 24 months. We observed high carriage rates up to 68% for S. pneumoniae , 71% for H. influenzae and 68% for M. catarrhalis at the age of 18 months. Reduced doseCRM197 schedules induced a slight reduction in overall pneumococcal carriage but no increases in the presence of H. influenzae and M. catarrhalis.
Bibliography:http://dx.doi.org/10.1016/j.vaccine.2011.08.049
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-News-1
ObjectType-Feature-3
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2011.08.049